Human Microbiome Market: Current Analysis and Forecast (2022-2028)

Global Human Microbiome Market is expected to grow at a significant rate of around 26.7% during the forecast period. Human microbiome is a collection of microorganisms that live on or within the human body. These microbiomes have shown a potential role in healthcare owing to their multiple functions, including enabling easy digestion, regulation of the immune system, and production of vitamins. Studies have estimated that the number of microbes present inside the human body can be beneficial for the management of several diseases such as cancer and for adopting novel therapies. This presents lucrative opportunities for drug developers and vaccine manufacturers surging the growth of the human microbiome market. Several key companies are getting funds to fasten the process of development of therapeutic drugs. For instance, in 2022, OptiBiotix Health Plc. signed an exclusive sales and distribution agreement with Nahdi medical Co. to help tackle the obesity epidemic.

Enterome Biosciences SA, Yakult Honsha Co., 4D Pharma, Second Genome, Seres Therapeutics, Vedanta Biosciences, Inc., AOBiome, Microbiome Therapeutics LLC, and OptiBiotix HEALTH PLC. are some of the key players in the market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.

Insights Presented in the Report:

"Amongst disease, cancer category to witness higher CAGR during the forecast period"

Based on disease, the market is segmented into obesity, infectious diseases, cancer, autoimmune diseases, metabolic & gastrointestinal disorders, and others. The cancer segment is expected to grow with high CAGR rates during the forecast period. It is attributed to the increase in incidences of cancer and the unmet need for targeted therapy. For instance, Enterome has developed OncoMimics, peptides derived from gut bacteria that mimic tumor-associated antigens in a wide range of cancers. The company's lead candidate, EO2401 is being evaluated in a phase-I/II clinical trial in combination with an immune checkpoint inhibitor for the management of glioblastoma.

"Amongst product type, the probiotics to hold a significant share in the market in 2020"

On the basis of product, the market is categorized into probiotics, prebiotics, diagnostic tests, drugs, medical foods, supplements, and others. Among these, probiotics to hold a significant share of the market in 2020 which is due to the numerous health benefits offered by them. Furthermore, athletes and yoga instructors are also giving emphasis on the health benefits of probiotics through social media and paid partnerships. The segment has also received significant investment, which is another factor propelling the market growth. For instance, in February 2020, Amorepacific Group inaugurated its novel green tea probiotics Research Centre for studying lactobacillus found in Jeju organic green tea.

"Amongst application, diagnostics category to witness higher CAGR during the forecast period"

Based on application, the market is bifurcated into diagnostics and therapeutics. The diagnostic segment is expected to witness high CAGR rates during the forecast period which is due to the rise of scientific and technological innovations in gene mapping and the advent of omics technologies. The companies have also adopted strategic alliances to maintain a strategic edge in the global market. For instance, in June 2022, Genetic Analysis AS entered into collaboration with Servatus Biopharmaceuticals Ltd to advance microbiome diagnostics.

"North America to hold a significant share in the market"

In 2020, North America held a significant share of the global human microbiome market. Several factors, including surge in the prevalence of lifestyle-related disorders, increasing awareness among individuals regarding preventive healthcare, and the rise in research and development of human microbiome are driving the growth of the market in the region. Apart from this, the presence of major key players and the development of a strong pipeline of human microbiome products is also boosting the market's growth. For instance, in 2020, Seres Therapeutics' stool-derived treatment for recurrent Clostridium difficile infection cleared phase III of clinical trials.

Reasons to buy this report:

The study includes market sizing and forecasting analysis validated by authenticated key industry experts.

The report presents a quick review of overall industry performance at one glance.

The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments.

Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.

The study comprehensively covers the market across different segments.

Deep dive regional level analysis of the industry.

Customization Options:

The global human microbiome market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.